Systems biology approaches to develop innovative strategies for lung cancer therapy

Cell Death and Disease

Volumn 5, Issue , 2014, Pages

  Viktorsson, K ^a   Lewensohn, R ^a   Zhivotovsky, B ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LOMONOSOV MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

lung cancer; personalized cancer medicine; systems biology; therapeutic strategies

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MICRORNA; PROTEIN; SMALL INTERFERING RNA;

CANCER PROGNOSIS; CANCER THERAPY; DNA LIBRARY; DNA MICROARRAY; DNA SEQUENCE; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; LIMIT OF DETECTION; LUNG ADENOCARCINOMA; LUNG CANCER; MOLECULAR GENETICS; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN METHYLATION; PROTEIN PROCESSING; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SULFATION; SYSTEMS BIOLOGY; TREATMENT RESPONSE; FEMALE; LUNG NEOPLASMS; MALE; PROCEDURES;

FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; SYSTEMS BIOLOGY;

EID: 84921926221     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.28     Document Type: Review

References (91)

1. Higgins MJ, Ettinger DS. Chemotherapy for lung cancer: the state of the art in 2009. Expert Rev Anticancer Ther 2009; 9: 1365-1378.
2. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
3. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009; 119: 1727-1740.
4. Viktorsson K, Lewensohn R. Apoptotic signaling pathways in lung cancer. J Thorac Oncol 2007; 2: 175-179.
5. Arrell DK, Terzic A. Network systems biology for drug discovery. Clin Pharmacol Ther 2010; 88: 120-125.
6. Ocak S, Sos ML, Thomas RK, Massion PP. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J 2009; 34: 489-506.
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
8. Chandra H, Reddy PJ, Srivastava S. Protein microarrays and novel detection platforms. Expert Rev Proteomics 2011; 8: 61-79.
9. Pierobon M, Vanmeter AJ, Moroni N, Galdi F, Petricoin EF 3rd. Reverse-phase protein microarrays. Methods Mol Biol 2012; 823: 215-235.
10. Indovina P, Marcelli E, Pentimalli F, Tanganelli P, Tarro G, Giordano A. Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery. Mass Spectrom Rev 2013; 32: 129-142.
11. Olsen JV, Mann M. Status of large-scale analysis of post-translational modifications by mass spectrometry. Mol Cell Proteomics 2013; 12: 3444-3452.
12. Zinovyev A, Fourquet S, Tournier L, Calzone L, Barillot E. Cell death and life in cancer: mathematical modeling of cell fate decisions. Adv Exp Med Biol 2012; 736: 261-274.
13. Cohen D, Kuperstein I, Barillot E, Zinovyev A, Calzone L. From a biological hypothesis to the construction of a mathematical model. Methods Mol Biol 2013; 1021: 107-125.
14. Calzone L, Tournier L, Fourquet S, Thieffry D, Zhivotovsky B, Barillot E et al. Mathematical modelling of cell-fate decision in response to death receptor engagement. PLoS Comput Biol 2010; 6: e1000702.
15. Petrosyan F, Daw H, Haddad A, Spiro T, Sood R. Gene expression profiling for early-stage NSCLC. Am J Clin Oncol 2013; e-pub ahead of print 19 April 2013.
16. Rosell R, Taron M, Massuti B, Mederos N, Magri I, Santarpia M et al. Predicting response to chemotherapy with early-stage lung cancer. Cancer J 2011; 17: 49-56.
17. Alamgeer M, Ganju V, Watkins DN. Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol 2013; 13: 394-401.
18. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
19. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012.
20. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013; 382: 720-731.
21. Network CGAR. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
22. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
23. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013; 31: 1070-1080.
24. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011; 471: 523-526.
25. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011; 1: 352-365.
26. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012; 18: 521-528.
27. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genetics 2012; 44: 1104-1110.
28. Sos ML, Dietlein F, Peifer M, Schottle J, Balke-Want H, Muller C et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA 2012; 109: 17034-17039.
29. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010; 17: 547-559.
30. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448: 807-810.
31. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203.
32. Salim H, Arvanitis A, de Petris L, Kanter L, Haag P, Zovko A et al. miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression. Genes Chromosomes Cancer 2013; 52: 895-911.
33. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009; 69: 3256-3261.
34. Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2009; 2: 1039-1049.
35. Stahl S, Kaminskyy VO, Efazat G, Hyrslova Vaculova A, Rodriguez-Nieto S, Moshfegh A et al. Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. Cell Death Dis 2013; 4: e454.
36. Stahl S, Branca RM, Efazat G, Ruzzene M, Zhivotovsky B, Lewensohn R et al. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 2011; 10: 2566-2578.
37. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813-823.
38. Feng XD, Huang SG, Shou JY, Liao BR, Yingling JM, Ye X et al. Analysis of pathway activity in primary tumors and NCI60 cell lines using gene expression profiling data. Genomics Proteomics Bioinformatics 2007; 5: 15-24.
39. Merk J, Rolff J, Becker M, Leschber G, Fichtner I. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 2009; 36: 454-459.
40. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 2011; 47: 1231-1243.
41. Nemati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 2010; 16: 2352-2362.
42. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410: 1111-1116.
43. To MD, Quigley DA, Mao JH, Del Rosario R, Hsu J, Hodgson G et al. Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. Mol Cancer Res 2011; 9: 1339-1345.
44. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003; 4: 181-189.
45. Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, Meuwissen R et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 2011; 19: 244-256.
46. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18: 63-73.
47. Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011; 19: 652-663.
48. Van Laar K. Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer. BMC Med Genomics 2012; 5: 1-12.
49. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012; 9: 144-155.
50. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10: 1318-1325.
51. Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010; 70: 63-70.
52. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013; 368: 1101-1110.
53. Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J et al. Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin Cancer Res 2011; 17: 5562-5572.
54. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009; 4: e5133.
55. Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; 73: 2271-2280.
56. Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L et al. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer 2013; 80: 216-222.
57. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genetics 2009; 10: 704-714.
58. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-3756.
59. Sozzi G, Pastorino U, Croce CM. MicroRNAs and lung cancer: from markers to targets. Cell Cycle 2011; 10: 2045-2046.
60. Boeri M, Pastorino U, Sozzi G. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J 2012; 18: 268-274.
61. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009; 69: 5776-5783.
62. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010; 16: 430-441.
63. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010; 70: 36-45.
64. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011; 108: 3713-3718.
65. Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L. Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther 2013; 14: 12.
66. Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q et al. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res 2011; 71: 7670-7682.
67. Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res 2013; 19: 5423-5433.
68. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009; 284: 5731-5741.
69. Peng Y, Dai Y, Hitchcock C, Yang X, Kassis ES, Liu L et al. Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci USA 2013; 110: 15043-15048.
70. Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A et al. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer 2012; 107: 1361-1373.
71. Wang XC, Wang W, Zhang ZB, Zhao J, Tan XG, Luo JC. Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer. Radiat Oncol 2013; 8: 146.
72. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010; 70: 1793-1803.
73. Zang YS, Zhong YF, Fang Z, Li B, An J. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther 2012; 19: 773-778.
74. Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011; 30: 20.
75. Berghmans T, Ameye L, Willems L, Paesmans M, Mascaux C, Lafitte JJ et al. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer 2013; 82: 340-345.
76. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010; 70: 8288-8298.
77. Diaz-Garcia CV, Agudo-Lopez A, Perez C, Lopez-Martin JA, Rodriguez-Peralto JL, de Castro J et al. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis 2013; 34: 1031-1038.
78. Surova O, Akbar NS, Zhivotovsky B. Knock-down of core proteins regulating microRNA biogenesis has no effect on sensitivity of lung cancer cells to ionizing radiation. PLoS One 2012; 7: e33134.
79. Pernemalm M, De Petris L, Branca RM, Forshed J, Kanter L, Soria JC et al. Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism. J Proteome Res 2013; 12: 3934-3943.
80. Orre LM, Pernemalm M, Lengqvist J, Lewensohn R, Lehtio J. Up-regulation, modification, and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling. Mol Cell Proteomics 2007; 6: 2122-2131.
81. De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R et al. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer 2009; 63: 410-417.
82. Orre LM, Panizza E, Kaminskyy VO, Vernet E, Graslund T, Zhivotovsky B et al. S100A4 interacts with p53 in the nucleus and promotes p53 degradation. Oncogene 2013; 32: 5531-5540.
83. Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faca VM, Kelly-Spratt K et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 2011; 20: 289-299.
84. Marko-Varga G, Fehniger TE, Rezeli M, Dome B, Laurell T, Vegvari A. Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. J Proteomics 2011; 74: 982-992.
85. Zhang G, Fang B, Liu RZ, Lin H, Kinose F, Bai Y et al. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res 2011; 10: 305-319.
86. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 2008; 105: 14112-14117.
87. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natil Acad Sci USA 2008; 105: 692-697.
88. Schweppe DK, Rigas JR, Gerber SA. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 2013; 91C: 286-296.
89. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010; 6: 291-299.
90. Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F et al. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci USA 2013; 110: 12414-12419.
91. Yu Y, He J. Molecular classification of non-small-cell lung cancer: diagnosis, individualized treatment, and prognosis. Front Med 2013; 7: 157-171.